The FDA convenes experts this week to decide if compounding pharmacies can produce popular but unproven injectable peptides like TB-500 and BPC-157. Advocates cite grey market risks, while scientists warn of sparse human evidence and potential safety dangers.
FDA panel weighs regulation of unproven peptide therapies
✨ Enjoying this article? ✨
📱 Get more with the NewsNuggs iOS App →